Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity

Orthotopic liver transplantation (OLT) is the preferred treatment for selected patients with hepatitis B virus (HBV)‐related liver disease. This study aimed to (i) define long‐term outcomes following OLT for HBV; (ii) to quantify the incidence of HBV recurrence (rHBV) as it relates to anti‐HBV treat...

Full description

Saved in:
Bibliographic Details
Published in:Clinical transplantation 2013-11, Vol.27 (6), p.829-837
Main Authors: Campsen, Jeffrey, Zimmerman, Michael, Trotter, James, Hong, Johnny, Freise, Chris, Brown Jr, Robert S., Cameron, Andrew, Ghobrial, Mark, Kam, Igal, Busuttil, Ronald, Saab, Sammy, Holt, Curtis, Emond, Jean C., Stiles, Jessica B., Lukose, Thresiamma, Chang, Matthew S., Klintmalm, Göran
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Biological and medical sciences
Cancer
Ethnic Groups - statistics & numerical data
ethnicity
Female
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
Fundamental immunology
gender
Healthcare Disparities
Hepatitis B - ethnology
Hepatitis B - surgery
hepatitis B immunoglobulin
Hepatitis B virus
Hepatitis B virus - pathogenicity
Human viral diseases
Humans
Infectious diseases
liver transplant
Liver Transplantation
Male
Medical sciences
Middle Aged
Prognosis
recurrence
Retrospective Studies
Secondary Prevention
Sex Factors
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Survival Rate
Tissue, organ and graft immunology
Viral diseases
Viral hepatitis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Orthotopic liver transplantation (OLT) is the preferred treatment for selected patients with hepatitis B virus (HBV)‐related liver disease. This study aimed to (i) define long‐term outcomes following OLT for HBV; (ii) to quantify the incidence of HBV recurrence (rHBV) as it relates to anti‐HBV treatment; and (iii) to determine outcomes for specific patient subgroups. We performed a retrospective chart review of 738 patients undergoing OLT between 1985 and 2010 at seven US transplant centers and divided the patients into 3 eras, 1985–1994, 1995–2004, and 2005–2010, based on hepatitis B immunoglobulin and antiviral therapies. In Era 3, female gender (p = 0.002), recurrent hepatocellular cancer (p 
ISSN:0902-0063
1399-0012
DOI:10.1111/ctr.12224